Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pretax income is the income that a company earns before paying income taxes. Biotechnology Assets's pretax income for the
six
months ended in Dec. 2025 was €-0.74 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Dec. 2025 was €-1.60 Mil.
Biotechnology Assets's pretax margin was -34.83%.
During the past 13 years, Biotechnology Assets's highest Pretax Margin was 64.48%. The lowest was -137.96%. And the median was -86.25%.
During the past 13 years, Biotechnology Assets's highest Pretax Margin was 64.48%. The lowest was -137.96%. And the median was -86.25%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biotechnology Assets Pre-Tax Income Related Terms
Biotechnology Assets Pre-Tax Income Historical Data
* Premium members only.
The historical data trend for Biotechnology Assets's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XMAD:BST vs VRTX, REGN, RVMD: Pre-Tax Income Comparison
For the Biotechnology subindustry, Biotechnology Assets's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biotechnology Assets Pre-Tax Income vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Biotechnology Assets's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Biotechnology Assets's Pre-Tax Income falls into.
Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-1.60 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biotechnology Assets (XMAD:BST) has a Pre-Tax Income of €-1.60 Mil as of Dec. 2025. Pre-Tax Income is the total earnings before taxes but after all operating and interest expenses. View historical data on Biotechnology Assets and its competitors.
Is Biotechnology Assets' Pre-Tax Income too high?
Biotechnology Assets' current Pre-Tax Income is €-1.60 Mil. Overall, Biotechnology Assets has a GF Score™ of 19/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Biotechnology Assets' Pre-Tax Income compare to VRTX and REGN?
Biotechnology Assets' Pre-Tax Income of €-1.60 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pre-Tax Income for a Biotechnology company?
A good Pre-Tax Income depends on the Biotechnology industry context. However, Pre-Tax Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pre-Tax Income mean?
A high Pre-Tax Income can signal that a stock is expensive relative to its fundamentals. Pre-Tax Income is the total earnings before taxes but after all operating and interest expenses. View historical data on Biotechnology Assets and its competitors. Biotechnology Assets's current Pre-Tax Income is €-1.60 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biotechnology Assets stock overvalued right now?
Based on GuruFocus' analysis, Biotechnology Assets (XMAD:BST) is currently considered Modestly Undervalued. The stock's GF Value™ is €0.29, compared to a current price of €0.22 — trading 25.2% below its estimated fair value. The current Pre-Tax Income is €-1.60 Mil. Biotechnology Assets' overall GF Score™ is 19/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pre-Tax Income calculated?
Pre-Tax Income is calculated from a company's financial statements. For Biotechnology Assets (XMAD:BST), the current Pre-Tax Income is €-1.60 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biotechnology Assets (XMAD:BST) Overvalued in 2026?
Based on GuruFocus' analysis, Biotechnology Assets stock appears to be undervalued.
The current stock price of €0.22 is trading 25.2% below its estimated GF Value™ of €0.29.
GuruFocus considers Biotechnology Assets to be Modestly Undervalued.
Key valuation signals for XMAD:BST:
Pre-Tax Income: €-1.60 Mil
GF Value™: €0.29 vs. price of €0.22 (25.2% below fair value)
No single metric tells the full story. See the XMAD:BST stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biotechnology Assets SA is a clinical-stage biopharmaceutical company developing and producing biological products for the pharmaceutical and veterinarian sectors. It specializes in the prevention and treatment of niche diseases, such as orphan disease, antigens for new-generation vaccines, feed additives, and probiotics. Adl Bionatur offers a portfolio of non-therapeutic and therapeutic products to tier 1 and tier 2 animal health companies. The company's pipeline products include BNT006, BNT007, BNT010, and others.
19GF Score
Get the complete analysis for XMAD:BST
Pre-Tax Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:BST has been successfully added to your 
